Retinopathy of prematurity and risk factors: A prospective cohort study

BMC Pediatrics

Volumn 5, Issue , 2005, Pages

  Karna, Padmani ^a   Muttineni, Jyotsna ^b   Angell, Linda ^a   Karmaus, Wilfried ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; OXYGEN; STEROID; ANTIINFLAMMATORY AGENT; BETAMETHASONE; DEXAMETHASONE; GLUCOCORTICOID;

ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATHOGENESIS; PERINATAL PERIOD; PRENATAL PERIOD; PROSPECTIVE STUDY; RETROLENTAL FIBROPLASIA; RISK FACTOR; SURVIVAL; UNITED STATES; VERY LOW BIRTH WEIGHT; AFRICAN AMERICAN; CAUCASIAN; LUNG DISEASE; PREGNANCY; PREMATURE LABOR; PREMATURITY; RISK;

AFRICAN AMERICANS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; DEXAMETHASONE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GESTATIONAL AGE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; LUNG DISEASES; MALE; OBSTETRIC LABOR, PREMATURE; ODDS RATIO; OXYGEN; PREGNANCY; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; RETINOPATHY OF PREMATURITY; RISK FACTORS;

EID: 26444610321     PISSN: 14712431     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-5-18     Document Type: Article

References (40)

1. Purohit DM, Ellison RC, Zierler S, Miettinen OS, Nadas AS: Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants. Pediatrics 1985, 76:339-44.
2. Gibson DL, Sheps SB, Uh SH, Schechter MT, McCormick AQ: Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics 1990, 86:405-12.
3. Kinsey VE, Arnold HJ, Kalina RE, Stern L, Stahlman M, Odell G, Driscoll JM Jr, JH Elliott, J Payne, A Patz: PaO2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics 1977, 60:655-68.
4. Flynn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W, Cassady J, Schiffman J, Feldman HI, Bachynski B, Buckley E, et al.: A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992, 326:1050-4.
5. Avery GB, Glass P: Retinopathy of prematurity: progress report. Pediatr Ann 1988, 17:520, 530, 532-3.
6. Glass P, Avery GB, Subramanian KN, Keys MP, Sostek AM, Friendly DS: Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity. N Engl J Med 1985, 313:401-4.
7. Brooks SE, Marcus DM, Gillis D, Pirie E, Johnson MH, Bhatia J: The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Pediatrics 1999, 104:514-8.
8. Kim TI, Sohn J, Pi SY, Yoon YH: Postnatal risk factors of retinopathy of prematurity. Paediatr Perinat Epidemiol 2004, 18:130-4.
9. Ryan CA, Finer NN: Antenatal corticosteroid therapy to prevent respiratory distress syndrome. J Pediatr 1995, 126:317-9.
10. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement :1-24. Feb. 28-March 2, 1994
11. Planer RA, Ballard PL, Coburn CE, Boardman CR, Cnaan A, Morgan MA, Parer J: Antenatal corticosteroid (ANCS) use in preterm labor in the USA. Pediatric Research 1996, 39:110A.
12. Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, Kao HA, Chien CH: Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997, 100:E3.
13. Sobel DB, Philip AG: Prolonged dexamethasone therapy reduces the incidence of cryotherapy for retinopathy of prematurity in infants of less than 1 kilogram birth weight with bronchopulmonary dysplasia. Pediatrics 1992, 90:529-33.
14. Batton DG, Roberts C, Trese M, Maisels MJ: Severe retinopathy of prematurity and steroid exposure. Pediatrics 1992, 90:534-6.
15. Wright K, Wright SP: Lack of association of glucocorticoid therapy and retinopathy of prematurity. Arch Pediatr Adolesc Med 1994, 148:848-52.
16. Ramanathan R, Siassi B, deLemos RA: Severe retinopathy of pre-maturity in extremely low birth weight infants after short-term dexamethasone therapy. J Perinatol 1995, 15:178-82.
17. Halliday HL, Ehrenkranz RA: Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001:CD001145.
18. Halliday HL, Ehrenkranz RA: Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001:CD001146.
19. Halliday HL, Ehrenkranz RA: Moderately early (7-14 days) post-natal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001:CD001144.
20. An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984, 102:1130-4.
21. Stokes CS, Koch GG: Gategorical data analysis using the SAS system. SAS Institute 1995.
22. SAS/STAT software. In SAS Institute Inc Cary, N.C; 2002.
23. Italian multicentre study on retinopathy of prematurity. The Italian ROP Study Group. Eur J Pediatr 1997, 156:939-43.
24. Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, Phelps DL: Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1997, 115:604-8.
25. Tadesse M, Dhanireddy R, Mittal M, Higgins RD: Race, Candida sepsis, and retinopathy of prematurity. Biol Neonate 2002, 81:86-90.
26. Higgins RD, Mendelsohn AL, DeFeo MJ, Ucsel R, Hendricks-Munoz KD: Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol 1998, 116:601-5.
27. Smith LM, Qureshi N, Chao CR: Effects of single and multiple courses of antenatal glucocorticoids in preterm newborns less than 30 weeks' gestation. J Matern Fetal Med 2000, 9:131-5.
28. Banks BA, Cnaan A, Morgan MA, Parer JT, Merrill JD, Ballard PL, Ballard RA: Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 1999, 181:709-17.
29. Termote J, Schalij-Delfos NE, Donders AR, Cats BP: Do postnatal glucocorticoids and retinopathy of prematurity relate? Am J Perinatol 2000, 17:291-8.
30. Haroon Parupia MF, Dhanireddy R: Association of postnatal dexamethasone use and fungal sepsis in the development of severe retinopathy of prematurity and progression to laser therapy in extremely low-birth-weight infants. J Perinatol 2001, 21:242-7.
31. American Academy of Pediatrics. Section on Ophthalmology: Screening examination of premature infants for retinopathy of prematurity. A joint statement of the American Academy of Pediatrics, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Pediatrics 1997, 100:273.
32. American Academy of Pediatrics. Section on Ophthalmology: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2001, 108:809-811.
33. Reynolds JD, Dobson V, Quinn GE, Fielder AR, Palmer EA, Saunders RA, Hardy RJ, Phelps DL, Baker JD, Trese MT, Schaffer D, Tung B, CRYO-ROP and LIGHT-ROP Cooperative Study Groups: Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol 2002, 120:1470-1476.
34. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, et al.: Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001, 98:5804-8.
35. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M, Svensson E, Smith L, Weinberger D, et al.: IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002, 87:3413-6.
36. Bennett A, Wilson DM, Liu F, Nagashima R, Rosenfeld RG, Hintz RL: Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab 1983, 57:609-12.
37. Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995, 80:1548-55.
38. Lineham JD, Smith RM, Dahlenburg GW, King RA, Haslam RR, Stuart MC, Faull L: Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986, 13:37-46.
39. Smith WJ, Underwood LE, Keyes L, Clemmons DR: Use of insulin-like growth factor I (IGF-I) and IGF-binding protein measurements to monitor feeding of premature infants. J Clin Endocrinol Metab 1997, 82:3982-8.
40. Smith LE: Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl 2002, 91:26-8.